BML (4694) Q1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2024 earnings summary
10 Mar, 2026Executive summary
Net sales for Q1 FY2024 rose 0.9% year-over-year to ¥35,592 million, while operating profit declined 4.5% to ¥2,547 million and profit attributable to owners of parent fell 5.0% to ¥1,707 million.
Non-COVID-19 testing volumes remained solid, offsetting declines in COVID-19-related testing, but profit was pressured by higher material and personnel costs.
Financial highlights
Gross profit for Q1 FY2024 was ¥11,956 million, down from ¥12,068 million year-over-year.
Ordinary profit decreased 4.2% year-over-year to ¥2,649 million.
Basic earnings per share for Q1 FY2024 was ¥43.81, compared to ¥46.10 in Q1 FY2023.
Comprehensive income for Q1 FY2024 was ¥1,719 million, down from ¥1,813 million year-over-year.
Outlook and guidance
Full-year FY2024 guidance maintained: net sales ¥140,000 million (+1.5% YoY), operating profit ¥9,200 million (+0.4%), ordinary profit ¥9,700 million (+1.0%), profit attributable to owners of parent ¥6,100 million (+1.1%), EPS ¥156.47.
No revision to dividend forecast; full-year dividend expected at ¥120 per share.
Latest events from BML
- FY2024 saw core business growth and higher EBITDA, but cost pressures will weigh on FY2025 profits.4694
Q4 202410 Mar 2026 - Net sales and profit rose in 1H FY2024, with guidance reaffirmed and Qualis Cloud sales resumed.4694
Q2 202410 Mar 2026 - Year-over-year profit and sales growth driven by robust non-COVID-19 testing demand.4694
Q3 202410 Mar 2026 - Q1 FY2025 saw solid sales and profit growth, plus a major treasury share buyback announcement.4694
Q1 202510 Mar 2026 - Strong sales and profit growth driven by new customers, price optimization, and operational efficiency.4694
Q2 202510 Mar 2026 - Strong sales and profit growth led to upward forecast revisions, despite industry challenges.4694
Q3 202510 Mar 2026